Brought to you by 
Galderma looks to re-purpose drugs through deal with AstraZeneca
05 Apr 2011
Executive Summary
Galderma SA(therapies for skin conditions) has gained exclusive access to certain compounds in AstraZeneca PLC’s pipeline, which it will re-purpose into dermatology therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galderma looks to re-purpose drugs through deal with AstraZeneca
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice